Vijaya Diagnostic Centre Ltd. · NSE:VIJAYA
Vijaya Diagnostic Centre — Q3 FY2022 Earnings Presentation
39 slides from Vijaya Diagnostic Centre's earnings presentation, Feb 4, 2022
Slide 1: Cover letter to stock exchanges
February 4, 2022 To, To, Listing Department The Corporate Relations Department National Stock Exchange of India Limited, BSE Limited, Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, 25th Floor, Dalal Street Bandra (East), Mumbai- 400 051 Mumbai- 400 001 Company Code No. VIJAYA Compan
Slide 2: Investor Presentation Q3 & 9MFY22
Vijaya Diagnostic Centre Limited Investor Presentation Q3 & 9MFY22
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for
Slide 4: Q3 & 9MFY22 Financial Performance
Q3 & 9MFY22 Financial Performance
Slide 5: Q3 & 9MFY22 – Performance Snapshot
Q3 & 9MFY22 – Performance Snapshot Operational & Financial Highlights – Q3 FY22 Operational & Financial Highlights – 9M FY22 2.32 Mn 6.87 Mn Tests Tests INR 1,107.8 Mn INR 3,461.7 Mn Revenue Revenue 0.85 Mn 2.67 Mn Footfalls Footfalls INR 478.3 Mn INR 1,558.3 Mn 89 EBIDTA 89 EBIDTA Centres Centres (
Slide 6: Key Operational Highlights (1/2)
Key Operational Highlights (1/2) Annual YTD Quarterly Tests Performed (# in Million) 22% Y-o-Y 46% 6.87 2.36 2.32 7.91 1.91 6.99 7.09 4.71 FY19 FY20 FY21 9MFY21 9MFY22 Q3FY21 Q2FY22 Q3FY22 Footfalls (# in Million) 25% Y-o-Y 53% 2.67 2.79 2.63 2.38 0.87 0.85 1.75 0.68 FY19 FY20 FY21 9MFY21 9MFY22 Q3F
Slide 7: Key Operational Highlights (2/2)
Key Operational Highlights (2/2) Annual YTD Quarterly Revenue per Test (INR) COVID effect: In-line 531 562 524 with historical years 504 428 477 477 419 FY19 FY20 FY21 9MFY21 9MFY22 Q3FY21 Q2FY22 Q3FY22 Revenue per Footfall (INR) COVID effect: In-line 1,515 1,463 with historical years 1,431 1,299 1,
Slide 8: Revenue – COVID, COVID Allied and Non-COVID
Revenue – COVID, COVID Allied and Non-COVID (INR Mn) Annual YTD Quarterly Non-COVID Revenue 20% Y-o-Y 3,388 39% 3,123 2,947 1,019 1,022 2,926 2,121 855 FY19 FY20 FY21 9MFY21 9MFY22 Q3FY21 Q2FY22 Q3FY22 COVID & COVID Allied Revenue* % of Revenue 17.1% 19.9% 14.9% 14.4% 9.6% 7.8% 2% 644 526 514 40% Y-
Slide 9: Key Financial Highlights (1/2)
Key Financial Highlights (1/2) (INR Mn) Annual YTD Quarterly Revenue from Operations 31% 11% Y-o-Y 3,767 3,462 1,127 3,388 2,647 999 1,108 2,926 FY19 FY20 FY21 9MFY21 9MFY22 Q3FY21 Q2FY22 Q3FY22 EBITDA & EBITDA Margin (%) 37.0% 39.1% 44.1% 42.1% 45.0% 46.5% 45.4% 43.2% 40% 3% Y-o-Y 1,660 1,558 464 5
Slide 10: Key Financial Highlights (2/2)
Key Financial Highlights (2/2) Annual YTD Cash Flow from Operations / EBITDA (%) 84% 80% 78% 81% 77% FY19 FY20 FY21 9MFY21 9MFY22 Cash & Cash Equivalents (INR Mn) 2,277 1,729 2,349 2,069 1,215 FY19 FY20 FY21 9MFY21 9MFY22 Working Capital Days FY19 FY20 FY21 9MFY21 9MFY22 -13 -12 -13 -10 -16 Cash & C
Slide 11: Consolidated Profit & Loss Account – Q3 & 9MFY22
Consolidated Profit & Loss Account – Q3 & 9MFY22 (INR Mn) Particulars Q3FY22 Q3FY21 Y-o-Y Q2FY22 Q-o-Q 9MFY22 9MFY21 Y-o-Y Revenue from operations 1,107.8 998.8 11% 1,127.1 -2% 3,461.7 2,647.4 31% Cost of materials consumed 163.0 139.8 17% 162.4 0% 536.2 408.3 31% Employee benefits expense 182.2 151
Slide 12: Company Overview
VIJAYA fc 5) DIAGNOSTIC [WISAYA] CENTRE Company Overview The Pioneers in Diagnostic Medicare.
Slide 13: Vijaya at a Glance
Vijaya at a Glance Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 89 state-of-the-art centres spread across 15 cities 40+ 89 Mission Years of Experience Centres Quality Experience in delivering Quality Diagnostic Service State-of-the-art Facilities wi
Slide 14: Our Journey
Our Journey Awarded Brand of the year in diagnostic One of the earliest private diagnostic Recognized as one of the Best Imaging services by The CEO Magazine and service providers to be approved for Vijaya Diagnostic Centre centres in Hyderabad by The Week Telangana Healthcare Leadership award COVID
Slide 15: At the Forefront of Introducing New Technologies
At the Forefront of Introducing New Technologies Ultrasound & Nuclear Medicine Fourth Generation 1981 Echocardiography 1986 1993 CT Scan 1994 Offer Mammography facility Hawkeye Gamma Automated Microbiology Real Time RT-PCR Assays 2006 2003 Culture 2000 1999 Bone Densitometry Camera with SPECT & Flow
Slide 16: Our Pillars of Strength
Our Pillars of Strength 1 One of the leading players in India’s high growth diagnostics market 2 Integrated diagnostics provider offering one-stop solution 3 High brand recall driving customer stickiness 4 Robust technical capabilities and state-of-the-art technology 5 Experienced Board and strong m
Slide 17: Indian Diagnostics Market expected to Grow at a Healthy Trajectory
Indian Diagnostics Market expected to Grow at a Healthy Trajectory Indian Diagnostics Market Segment-wise breakup of Indian Diagnostic Market (INR Bn) Radiology Pathology 980 980 +13% +13% FY23E CAGR CAGR 275 - 285 43% - 44% 684 684 FY20 +13% - 14% 190 - 195 CAGR 43% 472 472 +14% CAGR South India 41
Slide 18: One of the leading players in India's high growth diagnostics market
One of the leading players in India’s high growth diagnostics market Telangana and Andhra Pradesh Market Size Vijaya’s Core Geographies Telangana and Andhra (INR Bn) Dominant Position in Pradesh (44 - 46% of South Telangana & India) Andhra Pradesh +14% 120 -130 Karimnagar CAGR Mancherial Nizamabad 8
Slide 19: Integrated Diagnostic service provider with extensive network
Integrated Diagnostic service provider with extensive network… National Reference Lab Vijaya Diagnostic Centre Flagship Centre #1 #1 Reference Lab Customers Hubs #23 Samples #11 Customer (Walk-in) Home Collection B2B Hospitals & Labs Sample Flow Patient Flow Diagnostic Centres / Spokes #65 Flagship
Slide 20: One-Stop Solutions for Pathology & Radiology
…offering One-Stop Solutions for Pathology & Radiology Complete Range of Diagnostic Services under One Roof Comprehensive and high quality integrated diagnostic services through our operational network 19
Slide 21: High brand recall driving customer stickiness
High brand recall driving customer stickiness Customer Centric Approach Quality Diagnostic Services B2C Revenue 90.0% 93.0% 92.0% Higher brand recall FY19 FY20 FY21 High share of walk-in customers Operational Metrics (INR) Sticky individual customer 1,431 1,228 1,214 “For excellence in Quality and “
Slide 22: Robust Technical Capabilities with State-of-the-art IT Infrastructure
Robust Technical Capabilities with State-of-the-art IT Infrastructure 5 Advanced Software to Manage Clinical Data 17 CT Machines PET CT / Gamma machines 20 198 Fully Integrated Radiology Advance Laboratory MRI Machines Radiologists, Lab Doctors & Information Systems (RIS) and Information Management
Slide 23: Experienced Board of Directors
Experienced Board of Directors Dr. S Surendranath Reddy - Executive Chairman Dr. D Nageshwar Reddy - Non-executive, Independent Director Founder of Vijaya with 40+ years of experience in building Vijaya as South India’s largest integrated diagnostic chain Chairman of Asian Institute of Gastroent
Slide 24: Strong Management Team
Strong Management Team Dr. S. Surendranath Reddy Mr. Sunil Chandra Kondapally Ms. Suprita Reddy Mr. Narasimha Raju K.A Ms. Anusha Kanumuru Executive Chairman Executive Director Chief Executive Officer Chief Financial Officer Company Secretary & Compliance Officer 40+ years of experience in With
Slide 25: Awards & Accolades
Awards & Accolades One of the Best Healthcare Indo Global Award for Company of the Year - Leading Diagnostic Chain of the India’s Greatest Leaders 2020-21 Brands 2021 Healthcare Excellence Healthcare Year Ms. Suprita Reddy - CEO 2021 2021 2021 2021 2021 Presented by Presented by Presented by Present
Slide 26: Shareholding Pattern
Shareholding Pattern Others Shareholding Pattern as of 31st December 2021 FII’s 3.9% Category % Holding 16.7% Kedaara Capital* 10.0% Fidelity Group#^ 6.6% Promoter & Promoter 14.6% Axis Mutual Fund^ 6.3% 54.8% group Aberdeen Standard Investments^ 4.6% 10.0% Nippon Life India Asset Management^ 1.9% D
Slide 27: Strategy Going Forward
VIJAYA fc 5) DIAGNOSTIC [WISAYA] CENTRE Strategy Going Forward
Slide 28: Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh
Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh Leveraging Existing Presence Given under-penetration of diagnostic market, we will continue to focus on Opening additional diagnostic centres through owned & franchisee model Mancherial Nizamabad Karimnagar Expanding network through s
Slide 29: Expand in Adjacent Geographies & East India
Expand in Adjacent Geographies & East India Network (9MFY22) East India Strategy Expand presence in East India given growing demand Replicate our successful hub and spokes model in East India Established a hub in Kolkata and plan is to set up additional diagnostic centres South India Strategy
Slide 30: Continued Focus on Providing Customer Centric Services and Offerings
Continued Focus on Providing Customer Centric Services and Offerings Preventive and Wellness Testing to Boost Demand for Diagnostics FY20E Industry Size FY23P CAGR: ~20% 101-108 61-68 Rest of the Wellness & Rest of the Wellness & market Preventive market Preventive 90% 9% - 10% 89% 11% FY20 FY23 Key
Slide 31: Financial & Operational Highlights
Financial & Operational Highlights
Slide 32: Robust Operational Metrics
Robust Operational Metrics Diagnostic Centre (Nos) Footfalls (Mn) Tests Performed (Mn) Impact of Covid- 19 on Walk-in Impact of 80 Customers Covid-19 73 2.79 2.63 7.91 61 2.38 6.99 7.09 FY19 FY20 FY21 FY19 FY20 FY21 FY19 FY20 FY21 Test per Footfall (Nos) Revenue per Test (INR) Revenue per Footfall (
Slide 33: Consistent Financial Performance
Consistent Financial Performance (INR Mn) Revenue EBIDTA PAT CAGR:13% 3,767 CAGR:24% 1,660 843 CAGR:36% 3,388 2,926 1,326 625 1,081 459 FY19 FY20 FY21 FY19 FY20 FY21 FY19 FY20 FY21 EBIDTA Margin (%) PAT Margin (%) 710 bps 670 bps 44.1% 22.4% 37.0% 39.1% 18.5% 15.7% FY19 FY20 FY21 FY19 FY20 FY21 32
Slide 34: Sustainable Cash Generation & Increasing Return Ratios
Sustainable Cash Generation & Increasing Return Ratios Cash & Cash Equivalents CFO / EBIDTA (%) (INR Mn) 2,277 84% 80% 78% 1,729 1,215 FY19 FY20 FY21 FY19 FY20 FY21 RoCE Pre-Cash (%) RoE (%) 43% 22% 23% 23% 33% 30% FY19 FY20 FY21 FY19 FY20 FY21 ROCE (Pre-cash): PBIT ex Other income / (Total Assets –
Slide 35: Annexure
VIJAYA fc 5) DIAGNOSTIC [WISAYA] CENTRE Annexure The Pioneers in Diagnostic Medicare.
Slide 36: Consolidated Profit & Loss Account
Consolidated Profit & Loss Account (INR Mn) Particulars 9MFY22 FY21 FY20 FY19 Revenue from operations 3,462 3,767 3,388 2,926 Cost of materials consumed 536 571 439 405 Employee benefits expense 515 574 624 539 Other expenses 853 962 999 901 EBITDA 1,558 1,660 1,326 1,081 EBITDA % 45.0% 44.1% 39.1%
Slide 37: Consolidated Balance Sheet
Consolidated Balance Sheet (INR Mn) Assets Sep-21 Mar-21 Mar-20 Mar-19 EQUITY AND LIABILITIES Sep-21 Mar-21 Mar-20 Mar-19 NON-CURRENT ASSETS 3,954 3,021 2,959 2,689 EQUITY 4,212 3,592 2,741 2,069 Property, plant and equipment 1,660 1,358 1,398 1,437 Equity share capital 102 45 45 45 Capital work-in-
Slide 38: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (INR Mn) Particulars Sep-21 Mar-21 Mar-20 Mar-19 Cash Flow from Operating Activities Profit before Tax 821 1,121 834 653 Adjustment for Non-Operating Items 260 534 492 431 Operating Profit before Working Capital Changes 1,081 1,655 1,326 1,084 Changes in Working Capi
Slide 39: Thank You
THANK YOU Company Investor Relations Advisors Vijaya Diagnostic Centre Limited (VDCL) Orient Capital (a division of Link Group) Mr. Krishna Kiran – Investor Relations Ms. Ashish Chovatia : +91 99300 +91 90597 00749 44680 krishnakiran@vijayadiagnostic.in Ashish.chovatia@linkintime.co.in ir@vijayadiag
Vijaya Diagnostic Centre — Q3 FY2022 Earnings Presentation on 6ix